Rolls-Royce shares hit fresh highs in 2026 rally as valuation debate heats upLondon,
8 January 2026
1 min read

Rolls-Royce shares hit fresh highs in 2026 rally as valuation debate heats upLondon,

Jan 8, 2026, 09:00 (GMT)

Rolls-Royce shares rose again on Thursday, pushing further into a strong start to 2026 for the UK aero-engine maker. The stock hit 1,286 pence and was up 1.15% at 1,273.5 pence on delayed London market data. 1

The move is pulling in retail attention as well as bigger money. A Motley Fool column estimated a £10,000 stake bought a week ago would now be worth about £10,850, after an 8.5% gain in the first week of the year, and said the average 12-month target among analysts sat around 1,258p — close to where the shares have been trading. https://www.fool.co.uk/2026/01/08/10000-invested-in-rolls-royce-shares-just-1-week-ago-is-now-worth/ 2

The timing matters because defence-linked stocks across Europe are running hot, giving the sector a tailwind. An index of aerospace and defence companies was up around 2% by 0816 GMT after U.S. President Donald Trump said he wanted a $1.5 trillion military budget next year, Reuters reported. 3

A separate Yahoo Finance piece argued the shares could be “gearing up” for another big move, pointing to what it called still-building earnings momentum after a sharp two-year rise. https://uk.finance.yahoo.com/news/rolls-royce-share-price-gearing-074000525.html 4

Not everyone is comfortable with the price. Simply Wall St said the shares had risen 2.9% in a day, 8.3% over a week and 13.6% over a month at the time it reviewed the stock on Jan. 6, and put a “narrative” fair value at about £11.98 versus a £12.32 last close. It noted Rolls-Royce trades on a price-to-earnings ratio — a common measure that compares the share price to profit — of 17.8 times, and cited analyst targets ranging from £14.4 to £2.4. https://simplywall.st/stocks/gb/capital-goods/lse-rr./rolls-royce-holdings-shares/news/assessing-rolls-royce-holdings-lserr-valuation-after-strong

Rolls-Royce’s own story is still anchored to cash and delivery. In its last trading update in November, Chief Executive Tufan Erginbilgic said performance “builds further confidence” in 2025 guidance for underlying operating profit of £3.1 billion to £3.2 billion and free cash flow — cash left after running costs and investment — of £3.0 billion to £3.1 billion, despite “continued supply chain challenges”. The company also said it had completed £0.9 billion of a planned £1 billion share buyback by end-October and will announce full-year results on Feb. 26, 2026. 5

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Fresh Lloyds, Barclays and NatWest price targets hint at more upside for UK bank sharesLONDON,
Previous Story

Fresh Lloyds, Barclays and NatWest price targets hint at more upside for UK bank sharesLONDON,

Compass Group shares hit a 12-month low early as London market slips; dividend clock ticks
Next Story

Compass Group shares hit a 12-month low early as London market slips; dividend clock ticks

Go toTop